SPECIAL NOTICE
65 -- Intent to Sole Source VISN Wide Radiopharmaceutical Pluvicto Blanket purchase agreement (BPA)
- Notice Date
- 6/12/2024 6:28:13 AM
- Notice Type
- Special Notice
- NAICS
- 325412
— Pharmaceutical Preparation Manufacturing
- Contracting Office
- 249-NETWORK CONTRACT OFFICE 9 (36C249) MURFREESBORO TN 37129 USA
- ZIP Code
- 37129
- Solicitation Number
- 36C24924Q0314
- Response Due
- 6/27/2024 8:00:00 AM
- Archive Date
- 09/25/2024
- Point of Contact
- Christina Lawrence, Contract Specialist, Phone: 615-225-3426
- E-Mail Address
-
Christina.Lawrence2@va.gov
(Christina.Lawrence2@va.gov)
- Awardee
- null
- Description
- INTENT TO SOLE SOURCE This notice is being published in accordance with Federal Acquisition Regulation (FAR) Subpart 5.101 requiring dissemination of information for proposed contract actions. The Department of Veterans Affairs (VA), Network Contracting Office (NCO) 09, located at 1639 Medical Center Parkway, Suite 204, Murfreesboro, TN 37129 issuing an intent to award a single source blanket purchase agreement, five (5) ordering periods to Navartis Pharmaceuticals Corporation located at One Health Plaza, East Hanover, NJ 07936-1080 under FAR 13.106-1(b) and FAR 13.303 Blanket Purchase Agreements. The North American Industry Classification System (NAICS) for this requirement is 325412, Pharmaceutical Preparation Manufacturing. The Federal Supply Class (FSC) is 6505, Drugs and Biologicals. The Small Business Administration (SBA) size standard for this sector is 1,300 Employees. VISN 9 VA Medical Center requires manufacture and delivery of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) a radioactive therapy treatment agent indicated for prostate cancer treatment. VISN 9 VA Medical Center estimated to purchase Pluvicto in quantities listed below: NDC# Description Estimated quantities UI Ordering Period 1 69488-0010-61 PLUVICTO :: LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML 261 EA Ordering Period 2 69488-0010-61 PLUVICTO :: LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML 279 EA Ordering Period 3 69488-0010-61 PLUVICTO :: LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML 298 EA Ordering Period 4 69488-0010-61 PLUVICTO :: LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML 317 EA Ordering Period 5 69488-0010-61 PLUVICTO :: LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML 331 EA See attached Statement of Work. The Places of Performance are listed below: James J. Quillen Veterans Affairs Medical Center Nuclear Medicine Dept Lamont Street & Veterans Way Johnson City, TN 37684 Tennessee Valley Healthcare System Nuclear Medicine Dept 1310 24th Avenue South Nashville, TN 37212 Alvin C. York Veterans Affairs Medical Center 3400 Lebanon Pike Murfreesboro, TN 37129 Troy Bowling Veterans Affairs Medical Center Nuclear Medicine Dept 1101 Veterans Drive Lexington, KY 40502 Lt. Col Luke Weathers Veterans Affairs Medical Center Nuclear Medicine Dept 116 N Pauline Street Memphis, TN 38105 Robley Rex Veterans Affairs Medical Center Robley Rex Veterans Affairs Medical Center Nuclear Medicine Dept HOT LAB Nuclear Medicine Dept HOT LAB 800 Zorn Avenue 4906 Brownsboro Road Louisville, Kentucky 40206-1499 Louisville, KY 40222 Estimated Period of Performance: Ordering period 1: 12/01/2024-11/30/2025 Ordering period 2: 12/01/2025-11/30/2026 Ordering period 3: 12/01/2026-11/30/2027 Ordering period 4: 12/01/2027-11/30/2028 Ordering period 5: 12/01/2028-11/30/2029 Capability statement /information sought: Response to this announcement shall not to exceed 5 pages and should include the following information: (1) A tailored capability statement indicating the firm s ability to provide a product and related services; (2) The respondents SAM UEI number, organization name, address, point of contact, and size and type of business (e.g., SDVOSB/VOSB, etc,) pursuant to the applicable NAICS code; (3) Information should be provided electronically in a Microsoft Word or Adobe PDF format. This notice of intent is not a request for competitive quotes. However, interested parties may identify their interest and capability to respond to the requirement and submit capability statement no later than 10:00 am., CT, Wednesday June 27, 2024 to: Christina.Lawrence2@va.gov. Responses received will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses received to this notice is solely within the discretion of the Government. If no written response is received within the closing date of this notice, a single source blanket purchase agreement award will be made to Navartis Pharmaceuticals Corporation without any further notice. Disclaimer and Important Notes: This notice does not obligate the Government to award an agreement or otherwise pay for the information provided in response to this notice. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. However, responses to this notice will not be considered adequate responses to a notice.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/cef60ddbd8044efa8913bd308f4fbe7a/view)
- Record
- SN07094408-F 20240614/240612230111 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |